Histiocytic and Dendritic Cell Neoplasm clinical trials at UC Cancer
1 research study open to eligible people
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial
open to eligible people ages 12 months to 21 years
This phase II pediatric MATCH treatment trial studies how well selpercatinib works in treating patients with solid tumors that may have spread from where they first started to nearby tissue, lymph nodes, or distant parts of the body (advanced), lymphomas, or histiocytic disorders that have activating RET gene alterations. Selpercatinib may block the growth of cancer cells that have specific genetic changes in an important signaling pathway (called the RET pathway) and may reduce tumor size.
at UC Davis UCLA UCSF
Our lead scientists for Histiocytic and Dendritic Cell Neoplasm research studies include Theodore B. Moore Marcio H. Malogolowkin Arun A. Rangaswami Carla B. Golden.
Last updated: